Global Human Papillomavirus Associated Cancer Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight

Las Vegas, USA, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Global Human Papillomavirus Associated Cancer Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight 

Human Papillomavirus Associated Cancer Pipeline constitutes 50+ key companies continuously working towards developing 50+ Human Papillomavirus Associated Cancer treatment therapies, analyzes DelveInsight

DelveInsight’s Human Papillomavirus Associated Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Human Papillomavirus Associated Cancer pipeline domain. 

Some of the essential takeaways from the Human Papillomavirus Associated Cancer Pipeline report:

• DelveInsight’s Human Papillomavirus Associated Cancer Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ Human Papillomavirus Associated Cancer pipeline treatment therapies. 
• Some of the key Human Papillomavirus Associated Cancer companies proactively working to develop potential drug candidates to improve the Human Papillomavirus Associated Cancer treatment options include PDS Biotech, pHion Therapeutics Ltd., NexImmune, Precigen, Vaccitech, Nykode Therapeutics ASA, MedImmune LLC, Avalia Immunotherapies, Repertoire Immune Medicines, Kinopharma, Immunovaccine Inc., Inovio Pharmaceuticals, Voltron Therapeutics, Inc., SQZ Biotech, Kovina Therapeutics, Rubius Therapeutics, Transgene, BioNTech, 2A Pharma ApS, Genexine, Inc., Viracta Therapeutics, Inc., Myrio Therapeutics, Vault Pharma, GeoVax, IOVANCE Biotherapeutics, Inc., Advaxis, Astex Pharmaceuticals, Biond Biologics Ltd, BlueSky Immunotherapies, CHAIN Biotech, eTheRNA immunotherapies, ISA Pharmaceuticals, and others.
• Essential Human Papillomavirus Associated Cancer pipeline therapies such as PDS0101,  PTX_V1, PTX_V2, NEXI-003, PRGN-2009, VTP1100, VB10.16, MEDI0457, AVA1156, DPX-E7, VGX-3100, SQZ-PBMC-HPV, SQZ-AAC-HPV, SQZ-eAPC-HPV, HB-200, RTX-321, TG4001, BNT113, GX-188E, VPI-241, Axalimogene, ASTX660, delNS/E6E7, ISA101b, and others are under development in different phases of clinical trials.
• In July 2022, NexImmune, Inc. received IND clearance for the Company’s first cellular therapy product candidate addressing solid tumors. NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers.
• In July 2022, Voltron Therapeutics, Inc., announced that data from the previously announced Study '098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV-related cancers. This is a well-validated murine model of HPV-related cancers. VTX-067, a Self-Assembling Vaccine (SAV) targeting select peptides from HPV-related cancers, was developed using Voltron's Self Assembling Vaccine Platform. Voltron has executed an exclusive worldwide license for this technology from The Massachusetts General Hospital's (MGH) Vaccine and Immunotherapy Center (VIC).
• In July 2022, Repertoire Immune Medicines announced its research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to identify the immune system’s response at various stages of human papillomavirus-positive (HPV+) cancer, including initial oncogenesis and after successful treatment.
• In June 2022, Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute/NIH. With successful achievement of its milestones, the award will transition to a Small Business Innovation Research (SBIR) award and will provide approximately $2,400,000 over three years. The company received the grant to Advance Human Papillomavirus Cancer Treatment.
• In May 2022, Nykode Therapeutics announced positive interim results from its Phase 2 VB C-02 trial of VB10.16, its wholly-owned therapeutic cancer vaccine, in combination with the PD-L1 inhibitor atezolizumab in patients with HPV16-positive advanced cervical cancer. Interim results from 39 patients with a median follow up of 6 months show an ORR of 21%—including two patients who achieved a complete response and six who achieved a partial response—and a very high disease control rate of 64%. The trial enrolled a heavily pre-treated patient population with more than two thirds of the patients having received at least two previous systemic lines of treatment.
• In April 2022, SQZ Biotechnologies announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.
• In May 2021, Rubius Therapeutics, Inc. announced the publication of preclinical data in the peer-reviewed journal Nature Communications, for its lead artificial antigen-presenting (aAPC) cell program, RTX-321, for the potential treatment of human papillomavirus (HPV) 16-positive cancers.

Request a sample and discover more about the report offerings @ Human Papillomavirus Associated Cancer Emerging Therapies

The Human Papillomavirus Associated Cancer pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage Human Papillomavirus Associated Cancer pipeline products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Human Papillomavirus Associated Cancer pipeline landscape.

Human Papillomavirus Associated Cancer Overview

Human papillomavirus (HPV) infection is linked with several cancers such as cancer cervix, vagina, vulva, head and neck, anal, and penile carcinomas. Although there is a proven association of HPV with these cancers, questions regarding HPV testing, vaccination, and treatment of HPV-related cancers continue to remain unanswered. The present article provides an overview of HPV-associated cancers.

Find out more about the disease and recent cancer research developments @ Human Papillomavirus Associated Cancer Pipeline Assessment 

Human Papillomavirus Associated Cancer Pipeline Drugs

Learn more about the novel and emerging Human Papillomavirus Associated Cancer pipeline therapies @ Human Papillomavirus Associated Cancer Pipeline Analysis

Human Papillomavirus Associated Cancer Pipeline Therapeutics Assessment

The Human Papillomavirus Associated Cancer Pipeline report proffers an integral view of the Human Papillomavirus Associated Cancer emerging novel therapies segmented by Stage, Product Type,  Molecule Type,  Mechanism of Action and Route of Administration.

Scope of the Human Papillomavirus Associated Cancer Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Human Papillomavirus Associated Cancer Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Human Papillomavirus Associated Cancer Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
• Therapeutics Assessment By Human Papillomavirus Associated Cancer Route of Administration: Oral, Intravenous, Subcutaneous
• Therapeutics Assessment By Human Papillomavirus Associated Cancer Molecule Type: Small molecule, Gene therapy, Cell Therapy, Immunotherapy
• Therapeutics Assessment By Human Papillomavirus Associated Cancer Mechanism of Action: Immunostimulant, Cytotoxic T lymphocyte stimulant, Antigen presenting cell modulator, Helper-inducer T-lymphocyte stimulants, Natural killer cell stimulants, Natural killer T cell stimulants
• Key Human Papillomavirus Associated Cancer Companies: PDS Biotech, pHion Therapeutics Ltd., NexImmune, Precigen, Vaccitech, Nykode Therapeutics ASA, MedImmune LLC, Avalia Immunotherapies, Repertoire Immune Medicines, Kinopharma, Immunovaccine Inc., Inovio Pharmaceuticals, Voltron Therapeutics, Inc., SQZ Biotech, Kovina Therapeutics, Rubius Therapeutics, Transgene, BioNTech, 2A Pharma ApS, Genexine, Inc., Viracta Therapeutics, Inc., Myrio Therapeutics, Vault Pharma, GeoVax, IOVANCE Biotherapeutics, Inc., Advaxis, Astex Pharmaceuticals, Biond Biologics Ltd, BlueSky Immunotherapies, CHAIN Biotech, eTheRNA immunotherapies, ISA Pharmaceuticals, and others.
• Key Human Papillomavirus Associated Cancer Pipeline Therapies: PDS0101,  PTX_V1, PTX_V2, NEXI-003, PRGN-2009, VTP1100, VB10.16, MEDI0457, AVA1156, DPX-E7, VGX-3100, SQZ-PBMC-HPV, SQZ-AAC-HPV, SQZ-eAPC-HPV, HB-200, RTX-321, TG4001, BNT113, GX-188E, VPI-241, Axalimogene, ASTX660, delNS/E6E7, ISA101b, and others.

Dive deep into rich insights for emerging therapies and assessment, visit @ Human Papillomavirus Associated Cancer Pipeline and Emerging Therapies 

Table of Contents 

For further information on the current Human Papillomavirus Associated Cancer pipeline therapeutics, reach out @ Human Papillomavirus Associated Cancer Ongoing Clinical Trials 

Related Reports

Human Immunodeficiency Virus Type 1 Infection Pipeline

DelveInsight’s, “Human Immunodeficiency Virus Type 1 (HIV-1) Infection – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline landscape covering the pipeline drug profiles, including clinical and non-clinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type and key companies involved like United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics, and others.

Human Immunodeficiency Virus Type-1 Market

DelveInsight's "Human Immunodeficiency Virus Type-1 (HIV-1) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Human Immunodeficiency Virus Type-1 (HIV-1), historical and forecasted epidemiology, market trends, market drivers and barriers and other key HIV-1 companies such as Merck, ViiV Healthcare, Gilead Sciences, Janssen Pharmaceuticals, Mylan Laboratories Limited, TaiMed Biologics Inc, Theratechnologies Inc, Sanofi, GlaxoSmithKline, and others.

Human Papillomavirus 16-positive Cancers Market

DelveInsight's "Human Papillomavirus 16-positive (HPV16+) Cancers Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Human Papillomavirus 16-positive (HPV16+) Cancers, historical and forecasted epidemiology as well as the Human Papillomavirus 16-positive (HPV16+) Cancers market trends, market drivers and barriers and other key HPV16+ companies such as Merck, GlaxoSmithKline, PDS Biotechnology, Cue Biopharma, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Vaccibody AS, Roche, and many others.

Human Papillomavirus 16-positive Cancers Pipeline

DelveInsight’s, “Human Papillomavirus 16-positive (HPV16+) Cancers - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ pipeline drugs in Human Papillomavirus Vaccibody and 10+ key companies such as Genexine, Transgene, Inovio Pharmaceuticals, and others.

Human Papillomavirus (HPV) Pipeline

"Human Papillomavirus (HPV) Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Human Papillomavirus (HPV) market. A detailed picture of the Human Papillomavirus (HPV) pipeline landscape is provided, which includes the disease overview and Human Papillomavirus (HPV) treatment guidelines.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology

DelveInsight's "Human Immunodeficiency Virus Type 1 (HIV-1) Infection - Epidemiology Forecast to 2030" report delivers an in-depth understanding of the disease, historical and forecasted Human Immunodeficiency Virus Type 1 (HIV-1) Infection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Interested to know more about the recent oncology breakthroughs happenings? Take a look at the posts below

• Top Drugs To Watch in HIV (2025)
• A New Approach to HIV Treatment Landscape 
• Widespread Usage of HPV Vaccine Reduces Cervical Cancers and Precancers

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News